• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Significant rates of hormone therapy discontinuation in breast cancer patients

byMonica ParksandDavid Wang
June 12, 2015
in Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a prospective cohort study of over 3000 patients with breast cancer, more than 50% of patients discontinued their adjuvant hormone therapy by 5 years.

2. Risk factors for discontinuation of adjuvant hormone therapy in patients with breast cancer include family history of ovarian cancer, extremes in age, higher comorbidities, and use of co-current analgesics, antidepressants, sedatives, and GI medications.

Evidence Rating Level: 2 (Good)

Study Rundown: Adjuvant hormone therapy, such as aromatase inhibitors or tamoxifen, has been shown previously to significantly reduce the risk of recurrence and cancer-specific mortality in breast cancer patients. However, given the high frequency of treatment-related adverse events, previous studies have reported high rates of premature discontinuation of hormone therapy. However, there has been a limited number of studies that identify characteristics that increases risk of treatment discontinuation in this patient population. The purpose of this study was to identify predictors for discontinuation of adjuvant hormonal therapy among breast cancer patients. The authors prospectively followed over 3000 patients with breast cancer using national breast cancer and prescription drug registries in Sweden. After a follow-up period of 5 years, the authors found that over 50% of patients had premature discontinuation of hormone therapy. Risk factors associated with premature discontinuation included family history of ovarian cancer, age of diagnosis, high comorbidity scores, and use of co-current analgesia, antidepressants, sedatives, and gastrointestinal medications. The results of this study identifies key risk factors for discontinuation and support the development of targeted interventions to prevent future adjuvant hormone therapy discontinuation. However, the study is limited in the study design, as the use of registry data does not guarantee that the patient consumes the prescribed medication. Furthermore, use of symptom-relieving drugs may reflect other comorbid conditions unrelated to adjuvant treatment, which may cofound the results of this study.

Click to read the study in JCO

Relevant Reading: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials

In-Depth [prospective cohort]: This study included 3395 women diagnosed with breast cancer, treated in Sweden with adjuvant hormone therapy with tamoxifen or aromatase inhibitors between 2005 and 2008. Data was collected from the Stockholm-Gotland Breast Cancer Register and the Swedish Prescribed Drug Register. The primary outcome was discontinuation of adjuvant hormone therapy. Patients were monitored starting from their first prescription for hormone therapy until treatment discontinuation, death, recurrence, metastasis, endometrial cancer, venous thromboembolism and end of study period or completion of 5-year treatment. The authors collected information on baseline use of symptom-relieving drugs and hormone therapy, demographics, and comorbidities. At the conclusion of the study, baseline predictors for discontinuation included use of analgesics (HR: 1.33; 95% CI: 1.16-1.52), hypnotics/sedatives (HR: 1.24; 95% CI: 1.07-1.43) and gastrointestinal drugs (HR: 1.25; 95% CI: 1.08-1.43), as well as self-reported use of hormone replacement therapy (HR: 1.78; 95% CI: 1.14-2.76) during the first year of treatment. Other predictors included age <40 years (HR: 1.39; 95% CI: 1.08-1.78) or >65 years (HR: 1.15; 95% CI: 1.03-1.28) at diagnosis, higher Charlson comorbidity index (HR: 1.35; 95% CI: 1.03-1.76), and family history of ovarian cancer (HR: 1.55; 95% CI: 1.19-2.02).

RELATED REPORTS

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adjuvant chemotherapyBreast Cancer
Previous Post

Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors

Next Post

Integrative genomic analysis promising for diagnostic subtyping of lower-grade glioma

RelatedReports

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

January 25, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Next Post
BRAF V600E mutations linked with increased mortality in thyroid cancer

Integrative genomic analysis promising for diagnostic subtyping of lower-grade glioma

Endovascular treatment of intracranial aneurysms prevents long-term recurrence

Endovascular treatment of intracranial aneurysms prevents long-term recurrence

IUDs safe in population at high risk for STIs

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options